Information Provided By:
Fly News Breaks for November 4, 2016
TSRO
Nov 4, 2016 | 05:26 EDT
Citi analyst Robyn Karnauskas raised her price target for TESARO to $151 from $125 following the drugmaker's Q3 results. The stock closed yesterday down $3.07 to $120.28. The niraparib filing is on track while the Varubi launch is better than expectations, Karnauskas tells investors in a research note. She believes TESARO's immuno-oncology franchise is not getting credit and sees longer-term upside opportunities for niraparib. Karnauskas keeps a Buy rating on the shares.
News For TSRO From the Last 2 Days
There are no results for your query TSRO
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.